Floatz Rating
CC47/100
Confidence
Indicative
Sponsor
Calithera Biosciences, Inc
Modality
UNKNOWN
Development Phase
Phase 1
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
32Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02071862CT.gov Study of the Glutaminase Inhibitor CB-839 in Solid Tumors | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Gastrointestinal Stromal Tumor
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cbe (this asset) | Calithera Biosciences, Inc | P1 | CC · 47 |
| Midazolam | Blueprint Medicines Corporation | P4 | BBB |
| Regorafenib | Institut Bergonié | P4 | BBB |
| Esomeprazole | Erasmus Medical Center | P4 | BB |
| Caffeine | Markus Joerger | P4 | BB |
| Imatinib | M.D. Anderson Cancer Center | P2 | BB |
| Nilotinib | Novartis Pharmaceuticals | P4 | BB |
| Avapritinib | Blueprint Medicines Corporation | P3 | BB |
| Bezuclastinib | Cogent Biosciences, Inc. | P3 | BB |
+41 more in the Gastrointestinal Stromal Tumor cohort
Other indications for Cbe
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Fumaric Aciduria | — | P1 | CC · 47 |
| Triple-Negative Breast Carcinoma | — | P1 | CC · 44 |
| Mesothelioma | — | P1 | CC · 42 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Cbe in Gastrointestinal Stromal Tumor. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cbe-gastrointestinal-stromal-tumor
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →